Reverb Therapeutics Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$12M
- Investors
-
7
Reverb Therapeutics General Information
Description
Developer of a cytokine therapy designed for cancer treatment and promoting targeted immune activation while limiting toxicity. The company uses bispecific antibodies to localize endogenous cytokines to immune cells in the tumor microenvironment (TME) and overcome toxicity issues of exogenously delivered cytokines, enabling cancer patients and the healthcare sector to redirect endogenous cytokines already in the body to cells of interest and treat cancer.
Contact Information
Website
www.reverbtx.comCorporate Office
- 700 West Georgia Street
- Suite 2500
- Vancouver, British Columbia V7Y 1B3
- Canada
Corporate Office
- 700 West Georgia Street
- Suite 2500
- Vancouver, British Columbia V7Y 1B3
- Canada
Reverb Therapeutics Timeline
Reverb Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Seed Round | 19-Feb-2025 | $12M | Completed | Pre-Clinical Trials | ||
| 2. Seed Round | 15-Nov-2023 | Completed | Pre-Clinical Trials | |||
| 1. Accelerator/Incubator | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Reverb Therapeutics Patents
Reverb Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-12668627-B2 | Cytokine-based therapies and methods | Active | 02-Mar-2023 | ||
| US-12692305-B1 | Cytokine-based therapies and methods | Active | 02-Mar-2023 | ||
| US-12774329-B2 | Cytokine-based therapies and methods | Active | 02-Mar-2023 | ||
| US-20260347476-A1 | Cytokine-based therapies and methods | Pending | 02-Mar-2023 | ||
| AU-2024229625-A1 | Cytokine-based therapies and methods, comprising mono- and bispecific non-blocking anti- cytokine antibody | Pending | 02-Mar-2023 | C07K16/244 |
Reverb Therapeutics Signals
Reverb Therapeutics Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| InBC Investment Corp. (InBC) | Venture Capital | Minority | ||
| KdT Ventures | Venture Capital | Minority | ||
| Seido Capital | Venture Capital | Minority | ||
| Amplitude Ventures | Venture Capital | Minority | ||
| Finchley Healthcare Ventures | Venture Capital | Minority |
Reverb Therapeutics FAQs
-
When was Reverb Therapeutics founded?
Reverb Therapeutics was founded in 2023.
-
Where is Reverb Therapeutics headquartered?
Reverb Therapeutics is headquartered in Vancouver, Canada.
-
What is the size of Reverb Therapeutics?
Reverb Therapeutics has 10 total employees.
-
What industry is Reverb Therapeutics in?
Reverb Therapeutics’s primary industry is Other Healthcare Services.
-
Is Reverb Therapeutics a private or public company?
Reverb Therapeutics is a Private company.
-
What is Reverb Therapeutics’s current revenue?
The current revenue for Reverb Therapeutics is .
-
How much funding has Reverb Therapeutics raised over time?
Reverb Therapeutics has raised $12.5M.
-
Who are Reverb Therapeutics’s investors?
InBC Investment Corp. (InBC), KdT Ventures, Seido Capital, Amplitude Ventures, and Finchley Healthcare Ventures are 5 of 7 investors who have invested in Reverb Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process